What Accuray (NASDAQ:ARAY) is attempting to do is not easy, and that at least partially explains why the company continues to see lumpy progress on its path toward becoming a fully-fledged growth med-tech. It's hard enough to sell hospital capital equipment with a list price above $4 million, and harder still when competing against such well-established rivals as Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY) (rivals that were able to essentially push Siemens out of the market).
Making matters worse, Accuray's stock has gotten caught up in the same capital flight that has led to other growth med-techs like Novadaq, Heartware, and Insulet seeing share price declines between 15% and 25% over the past...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|